PKP2 and arrhythmogenic right ventricular cardiomyopathy: These findings reinforce prior evidence that PKP2 truncating variation explains the largest EF of ARVC in an independent, highly phenotyped population.1 Our findings also demonstrate that with exclusion of patients carrying disease-relevant phenotypes from the control population in MyCode and high-fidelity clinical phenotyping for definite ARVC, the true EF of PKP2 truncating variants is higher than predicted by our less well phenotyped clinical genetic testing cohort.